secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2024-07-22T23:59:59+00:00
Accession:  0000950170-24-085058
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma completes Phase 3 enrollment for efzofitimod; topline data Q3 2025
------------------------------------------------------------------------------

- Enrolled 268 patients in EFZO-FIT study, exceeding target enrollment.
- Trial conducted at 85 centers across 9 countries.
- Topline data expected in Q3 2025.
- Phase 3 study is pivotal, randomized, double-blind, placebo-controlled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024085058/0000950170-24-085058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024085058/atyr-20240722.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-085058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer